Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $160.00 short put and a strike $150.00 long put offers a potential 11.86% return on risk over the next 34 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $160.00 by expiration. The full premium credit of $1.06 would be kept by the premium seller. The risk of $8.94 would be incurred if the stock dropped below the $150.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 76.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Analysts’ Recommendations for AbbVie in June 2017
Thu, 15 Jun 2017 14:36:09 +0000
Of the 21 analysts covering AbbVie in June 2017, three have recommended “strong buys,” while six have recommended “buys.”
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
Thu, 15 Jun 2017 12:26:12 +0000
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
Tue, 13 Jun 2017 13:37:01 +0000
Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.
Amgen’s Multiple Myeloma Treatment, KYPROLIS® (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse
Mon, 12 Jun 2017 23:01:00 +0000
Today, the National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending carfilzomib in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma (RMM) who have received one prior therapy that does not include bortezomib. “It is great news that carfilzomib, in combination with dexamethasone, has been approved by NICE.
Copycat ‘biosimilars’ win fast track, but FDA says this Bay Area company must slow down
Mon, 12 Jun 2017 21:55:10 +0000
Despite a Supreme Court decision shaving six months off the time it would take a maker of a so-called biosimilar to get to market, Coherus BioSciences Inc. lost nearly a quarter of its value Monday as regulators held off on approving its lower-cost biologic copycat version of a blockbuster brand-name drug. Redwood City-based Coherus (CHRS) had asked the Food and Drug Administration to approve CHS-1701, its version of Amgen Inc.’s Neulasta. Neulasta, also known as pegfilgrastim, is the best-selling drug given to cancer chemotherapy patients.
Also on Market Tamer…
Follow Us on Facebook